To estimate the effect and safety of laparoscopic sleeve gastrectomy for metabolic syndrome.

Clinical data of 50 patients accepting laparoscopic sleeve gastrectomy were analyzed retrospectively. Body mass, body mass index (BMI), mean arterial pressure, serum triglyceride, high density lipoproteins, fasting plasma glucose, glycosylated hemoglobin A1c and obesity co-related diseases were recorded and compared preoperatively and 2 years after operation.

LSG were successfully completed in all patients, the mean operation time was (70.7±26.3) min, postoperative hospitalization time was (7.0±1.7) d. All patients were followed up for more than 2 years without perioperative mortality and postoperative severe complications. Three months after operation, body mass and BMI decreased significantly (P<0.05). In the 24 patients with hypertension, the average arterial pressure decreased significantly 1 months after operation and remained relatively stable thereafter (P<0.05). Among them, 15 patients returned to normal blood pressure in 2 years after operation, without oral antihypertensive drugs, the complete remission rate was 63%. In the 35 patients with hypertriglyceridemia, serum triglyceride decreased significantly 6 months after operation (P<0.05), while high density lipoprotein increased statistically 1 year after operation (P<0.05). In the 32 patients with type 2 diabetes, fasting plasma glucose decreased significantly 1 months after operation (P<0.05), and the same to glycosylated hemoglobin A1c (P<0.05). Among them, 12 patients were completely cured without drug treatment and the cure rate was 37.5%. Obesity-related diseases such as fatty liver, sleep apnea and joints degeneration, also improved in 2 years after operation.

LSG is effective and safe in the treatment of obesity. It can significantly reduce body weight, and cure or significantly improve related metabolic syndrome at the same time.